SCHEMBL17619552

SCHEMBL17619552

CCCC(=O)C1(C)CCN(Cc2ccccc2)C1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.50
DRD4 P21917 1/20 0.50
DRD3 P35462 1/20 0.50
CYP2D6 P10635 8/20 0.49
CYP3A4 P08684 3/20 0.49
TSHR P16473 2/20 0.49
ALDH1A1 P00352 2/20 0.47
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
ABL1 P00519 1/20 0.46
RIN1 Q13671 1/20 0.46
GAA P10253 1/20 0.46
CHRM2 P08172 1/20 0.45
CHRM3 P20309 1/20 0.45
OPRL1 P41146 1/20 0.44
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4293243 0.84 DRD2 (0.55) DRD2DRD4DRD3CYP2D6CYP3A4
SCHEMBL12372530 0.80 CYP2D6 (0.54) DRD2DRD4DRD3CYP2D6CYP3A4
SCHEMBL9377754 0.80 DRD2 (0.51) DRD2DRD4DRD3CYP2D6CYP3A4
SCHEMBL1269458 0.78 CYP2D6 (0.61) DRD2DRD4DRD3CYP2D6CYP3A4
SCHEMBL10084273 0.76 ABL1 (0.53) CYP2D6CYP3A4ALDH1A1CYP2C9CYP2C19
SCHEMBL13556689 0.76 CYP2D6 (0.60) CYP2D6CYP3A4TSHRALDH1A1GAA
SCHEMBL4817148 0.76 CYP3A4 (0.56) CYP2D6CYP3A4TSHRALDH1A1CYP2C9
SCHEMBL2262610 0.76 CYP3A4 (0.56) CYP2D6CYP3A4TSHRALDH1A1CYP2C9
SCHEMBL14716240 0.76 CYP2D6 (0.63) DRD2DRD4DRD3CYP2D6CYP3A4
SCHEMBL17130274 0.74 NPFFR1 (0.47) DRD2DRD4DRD3CYP2D6CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016042451-A1 2-[BIS(4-FLUOROPHENYL)METHYL]-2,7-DIAZASPIRO[4.5]DECAN-10-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN DOPAMINE-ACTIVE-TRANSPORTER (DAT) PROTEIN FOR THE TREATMENT OF E.G. ATTENTION DEFICIT DISORDER (ADD) SHIRE INTERNATIONAL GMBH (CH) 2016-03-24 WO disclosed